tradipitant
AssetAlso called Nereus, VLY-686, LY-686017
Neurokinin-1 (NK1) receptor antagonist
- Stage
- Approved
- Modality
- Small molecule
- Target
- TACR1
- 6
- Indications
- 3
- Trials
- 1
- Developer
Indications
7No named disease
Approved, open.fda.gov, Dec 30, 2025
Diabetic gastroparesis
Phase 3, Completed, NCT06836557, clinicaltrials.gov, Oct 27, 2026
Gastroparesis
Phase 3, Completed, NCT06836557, clinicaltrials.gov, Oct 27, 2026
4 more
In the full profile
- Target and mechanism1
- Owner and partners1
- Trials3
- Evidence for its targets1
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.